The immunoproteasome as a target in hematologic malignancies.
about
Clinical use of proteasome inhibitors in the treatment of multiple myelomaOverview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.PSMB9 codon 60 polymorphisms have no impact on the activity of the immunoproteasome catalytic subunit B1i expressed in multiple types of solid cancerCCR 20th anniversary commentary: Preclinical study of proteasome inhibitor bortezomib in head and neck cancer.Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.IKK inhibition increases bortezomib effectiveness in ovarian cancer.A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.Activity-based imaging probes of the proteasome.Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells.Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity.New proteasome inhibitors in myeloma.Proteasome inhibitors in acute leukemia.Ixazomib for the treatment of multiple myeloma.Oral ixazomib maintenance therapy in multiple myeloma.Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.Safety of ixazomib for the treatment of multiple myeloma.Bcl3 regulates pro-survival and pro-inflammatory gene expression in cutaneous T-cell lymphoma.Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration.(Immuno)proteasomes as therapeutic target in acute leukemia.The proteasome and proteasome inhibitors in multiple myeloma.Proteasome dysregulation in human cancer: implications for clinical therapies.Combined Effect of Bortezomib and Menadione Sodium Bisulfite on Proteasomes of Tumor Cells: The Dramatic Decrease of Bortezomib Toxicity in a Preclinical TrialProteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: Opportunity for combination therapy
P2860
Q28080999-BC71B0AB-A830-4364-964B-58CCBB2BEA56Q34788381-E99F15B7-CF98-4D6F-983C-B370EE45DD77Q34989194-82FA70CB-A08B-4573-8AEB-C99BB97A0F72Q35154029-0A867E26-3D7D-4A59-B97A-2D321292D0B5Q35895152-D00B4644-EEF6-4002-B98D-5FC3CA63FB0EQ36413454-27FF661C-0F49-4DE1-A6F3-E5C204EC6D4EQ36943923-D0D77653-87E2-4377-9891-6AB8F257A5AAQ37136304-D123F1BD-E7EC-4BBC-A317-252EB62B8BCEQ37377911-F0E39E8E-5566-434C-B3FB-EC751FCC0B9CQ37536497-26CE9769-9851-4C10-9FB1-F0FC6DBCA3FEQ37727613-9C1B140B-2591-4224-8801-C0ACC741257FQ38052079-BB5DC997-2FAF-42B3-87B4-98F4B3A70ABEQ38088003-5C724D9C-BC21-434F-B107-CD4D9A069732Q38542172-BA17F01D-8D50-4B9A-B162-6A9E509D846FQ38640514-D22285D8-B7B3-4B3D-B8A0-BF44DE3E6075Q39034873-F57D1304-B4C4-40FC-85EA-D672E57C564BQ39234159-108E7B58-692B-4D6F-983E-244202ADA071Q39404809-FA93C94D-979D-4EF3-A06E-46F652B60872Q42004035-CCCBEF9F-7473-4A12-BDF5-CB4745DFE68EQ42314593-C78CA6AE-F03A-4816-B2E3-075A66CDA4DFQ47131929-E566280C-B4A9-4ED2-B2FD-DBA38E8060D5Q47339695-B7B76675-9303-49C0-A04D-33154B5D03D3Q50077966-0B5AE79A-49E7-4D07-94A6-382D3579B0B5Q58697024-D1123B39-1F04-4E24-AE82-1A31417902F6Q58796147-932FD586-79F3-4544-8697-2D16218BDF6B
P2860
The immunoproteasome as a target in hematologic malignancies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The immunoproteasome as a target in hematologic malignancies.
@en
The immunoproteasome as a target in hematologic malignancies.
@nl
type
label
The immunoproteasome as a target in hematologic malignancies.
@en
The immunoproteasome as a target in hematologic malignancies.
@nl
prefLabel
The immunoproteasome as a target in hematologic malignancies.
@en
The immunoproteasome as a target in hematologic malignancies.
@nl
P2860
P1476
The immunoproteasome as a target in hematologic malignancies.
@en
P2093
Deborah J Kuhn
P2860
P304
P356
10.1053/J.SEMINHEMATOL.2012.04.003
P577
2012-07-01T00:00:00Z